{"id":"concomitant-temozolomide-tmz","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Temozolomide is a prodrug that is converted into its active form, MTIC, which then methylates DNA, leading to DNA damage and cell death. This mechanism is particularly effective in rapidly dividing cells, such as cancer cells.","oneSentence":"Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:25.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma multiforme"},{"name":"Anaplastic astrocytoma"}]},"trialDetails":[{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT03663725","phase":"PHASE3","title":"Treatment Intensification With Temozolomide in Adults With a Glioblastoma","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-13","conditions":"Glioblastoma","enrollment":486},{"nctId":"NCT05109728","phase":"PHASE1","title":"A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Glioblastoma","enrollment":65},{"nctId":"NCT04396860","phase":"PHASE2, PHASE3","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":159},{"nctId":"NCT05765812","phase":"PHASE1, PHASE2","title":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2023-05-15","conditions":"Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III","enrollment":116},{"nctId":"NCT03405792","phase":"PHASE2","title":"Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-23","conditions":"Glioblastoma, Glioblastoma, WHO Grade IV","enrollment":40},{"nctId":"NCT05635734","phase":"PHASE1, PHASE2","title":"Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cantex Pharmaceuticals","startDate":"2023-09-05","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT07389278","phase":"PHASE1, PHASE2","title":"Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)","status":"NOT_YET_RECRUITING","sponsor":"Sabine Mueller, MD, PhD","startDate":"2026-03-09","conditions":"Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma","enrollment":97},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT02179086","phase":"PHASE2","title":"Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2014-12-04","conditions":"Glioblastoma","enrollment":606},{"nctId":"NCT06095375","phase":"PHASE1","title":"Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2022-07-04","conditions":"Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma","enrollment":21},{"nctId":"NCT02344355","phase":"PHASE2","title":"A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bryan Allen","startDate":"2017-03-13","conditions":"Glioblastoma Multiforme","enrollment":90},{"nctId":"NCT03212742","phase":"PHASE1, PHASE2","title":"Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2017-09-04","conditions":"Malignant Gliomas, Radiotherapy, PARP Inhibitor","enrollment":91},{"nctId":"NCT04900792","phase":"PHASE1","title":"A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bryan Allen","startDate":"2023-02-28","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":17},{"nctId":"NCT05052957","phase":"PHASE2","title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2023-01-20","conditions":"Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma","enrollment":16},{"nctId":"NCT04945148","phase":"PHASE2","title":"Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2024-05-10","conditions":"Glioblastoma, IDH-wildtype","enrollment":640},{"nctId":"NCT05342883","phase":"PHASE4","title":"GammaTile and Stupp in Newly Diagnosed GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"GT Medical Technologies, Inc.","startDate":"2022-08-17","conditions":"Glioblastoma","enrollment":61},{"nctId":"NCT03149575","phase":"PHASE3","title":"VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","status":"TERMINATED","sponsor":"DelMar Pharmaceuticals, Inc.","startDate":"2017-10-27","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":2},{"nctId":"NCT05190315","phase":"PHASE1","title":"Chlorpromazine and Standard of Care in Glioblastoma","status":"COMPLETED","sponsor":"Mohammed Milhem","startDate":"2022-01-28","conditions":"Glioblastoma Multiforme","enrollment":10},{"nctId":"NCT04471844","phase":"NA","title":"Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"NovoCure Ltd.","startDate":"2020-12-08","conditions":"Glioblastoma Multiforme","enrollment":981},{"nctId":"NCT04477200","phase":"PHASE1","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-08-05","conditions":"Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV","enrollment":68},{"nctId":"NCT06551909","phase":"NA","title":"Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2024-08-31","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT01777919","phase":"PHASE2","title":"Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform","status":"NOT_YET_RECRUITING","sponsor":"Olympion Medical Center","startDate":"2027-01","conditions":"Glioblastoma Multiforme","enrollment":32},{"nctId":"NCT04881032","phase":"PHASE1, PHASE2","title":"AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Jean Perrin","startDate":"2022-03-07","conditions":"Glioblastoma","enrollment":66},{"nctId":"NCT04280848","phase":"PHASE2","title":"Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2020-05-26","conditions":"Glioblastoma","enrollment":67},{"nctId":"NCT03395587","phase":"PHASE2","title":"Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2018-03-06","conditions":"Glioblastoma","enrollment":136},{"nctId":"NCT05565521","phase":"PHASE2","title":"UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-12-13","conditions":"Glioblastoma Multiforme, Adult, Glioblastoma, IDH-mutant","enrollment":55},{"nctId":"NCT06012695","phase":"PHASE1, PHASE2","title":"NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Novelwise Pharmaceutical Corporation","startDate":"2023-08-11","conditions":"Malignant Neoplasm, Malignant Neoplasm of Brain","enrollment":79},{"nctId":"NCT01985087","phase":"PHASE1, PHASE2","title":"A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Louisville","startDate":"2014-09","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT06595186","phase":"PHASE2","title":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","status":"RECRUITING","sponsor":"JenKem Technology Co., Ltd.","startDate":"2022-10-31","conditions":"Glioblastoma Multiforme (GBM)","enrollment":25},{"nctId":"NCT01837862","phase":"PHASE1, PHASE2","title":"A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas","status":"COMPLETED","sponsor":"Julie Krystal","startDate":"2013-10-22","conditions":"Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic","enrollment":36},{"nctId":"NCT06346821","phase":"","title":"Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data","status":"COMPLETED","sponsor":"Sichuan University","startDate":"2022-11-22","conditions":"Glioblastoma Multiforme","enrollment":181},{"nctId":"NCT02546102","phase":"PHASE3","title":"Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma","status":"SUSPENDED","sponsor":"Precision Life Sciences Group","startDate":"2024-12","conditions":"Glioblastoma Multiforme","enrollment":234},{"nctId":"NCT00589875","phase":"PHASE2","title":"Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2007-03","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":52},{"nctId":"NCT03466450","phase":"PHASE1, PHASE2","title":"Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2018-03-15","conditions":"Glioblastoma","enrollment":75},{"nctId":"NCT06330337","phase":"PHASE3","title":"Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma","status":"RECRUITING","sponsor":"The Third Affiliated hospital of Zhejiang Chinese Medical University","startDate":"2024-04-01","conditions":"Glioma","enrollment":58},{"nctId":"NCT06297512","phase":"PHASE2","title":"Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).","status":"RECRUITING","sponsor":"Iacopo Sardi","startDate":"2022-12-09","conditions":"Glioblastoma","enrollment":20},{"nctId":"NCT03425292","phase":"PHASE1","title":"A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2018-03-01","conditions":"Newly Diagnosed High Grade Glioma","enrollment":49},{"nctId":"NCT03463265","phase":"PHASE2","title":"Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Aadi Bioscience, Inc.","startDate":"2018-08-01","conditions":"High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma","enrollment":62},{"nctId":"NCT00626990","phase":"PHASE3","title":"Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-12","conditions":"Brain and Central Nervous System Tumors","enrollment":751},{"nctId":"NCT02991456","phase":"PHASE2","title":"Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-10-09","conditions":"Chemo-radiation Induced Nausea and Vomiting","enrollment":48},{"nctId":"NCT04967690","phase":"PHASE1","title":"A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM","status":"UNKNOWN","sponsor":"Double Bond Pharmaceutical AB","startDate":"2024-01","conditions":"Newly Diagnosed Glioblastoma","enrollment":27},{"nctId":"NCT05600491","phase":"PHASE3","title":"A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-11-08","conditions":"Anaplastic Oligoastrocytoma, Glioblastoma","enrollment":78},{"nctId":"NCT03243461","phase":"PHASE3","title":"International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)","status":"UNKNOWN","sponsor":"University of Göttingen","startDate":"2018-07-17","conditions":"Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III","enrollment":167},{"nctId":"NCT04614493","phase":"PHASE2","title":"Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-11","conditions":"Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type), Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide","enrollment":66},{"nctId":"NCT01587144","phase":"PHASE2","title":"Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-06-19","conditions":"Glioblastoma Multiforme","enrollment":18},{"nctId":"NCT03906448","phase":"PHASE2","title":"FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma","status":"TERMINATED","sponsor":"University of Florida","startDate":"2019-05-20","conditions":"Astrocytoma, Grade II, Astrocytoma, Grade III","enrollment":1},{"nctId":"NCT02903069","phase":"PHASE1","title":"Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-08-17","conditions":"Glioblastoma, Malignant Glioma","enrollment":66},{"nctId":"NCT04829097","phase":"PHASE3","title":"Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-11-01","conditions":"Glioblastoma","enrollment":80},{"nctId":"NCT01987830","phase":"NA","title":"Bevacizumab w / Temozolomide PET & Vascular MRI For GBM","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-11","conditions":"Recurrent Glioblastoma","enrollment":13},{"nctId":"NCT01390948","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-10-18","conditions":"High Grade Glioma","enrollment":124},{"nctId":"NCT04388033","phase":"PHASE1, PHASE2","title":"Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-12","conditions":"Glioblastoma, Glioma, Neoplasms, Neuroepithelial","enrollment":10},{"nctId":"NCT04224441","phase":"PHASE2","title":"Repurposing Chlorpromazine in the Treatment of Glioblastoma","status":"UNKNOWN","sponsor":"Marco G Paggi, MD, PhD","startDate":"2019-12-15","conditions":"Glioblastoma Multiforme, MGMT-Unmethylated Glioblastoma","enrollment":41},{"nctId":"NCT03168919","phase":"NA","title":"Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2016-10-06","conditions":"Glioma","enrollment":5},{"nctId":"NCT00900757","phase":"PHASE2","title":"Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-08","conditions":"Malignant Glioma","enrollment":57},{"nctId":"NCT02364206","phase":"PHASE1, PHASE2","title":"Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2015-06-08","conditions":"Adult Glioblastoma","enrollment":18},{"nctId":"NCT03778541","phase":"PHASE3","title":"HFSRT With Concurrent TMZ for Large BMs","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-12-03","conditions":"Brain Metastases, Chemotherapy, Radiotherapy","enrollment":224},{"nctId":"NCT02520635","phase":"","title":"Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2015-01","conditions":"Glioblastoma","enrollment":180},{"nctId":"NCT00486603","phase":"PHASE1, PHASE2","title":"Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-10-29","conditions":"Brain and Central Nervous System Tumors","enrollment":92},{"nctId":"NCT02337426","phase":"PHASE1","title":"Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-02-13","conditions":"Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma","enrollment":12},{"nctId":"NCT00262730","phase":"PHASE2","title":"Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-01","conditions":"Glioblastoma Multiforme","enrollment":97},{"nctId":"NCT03869242","phase":"NA","title":"NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2018-10-01","conditions":"Glioblastoma","enrollment":60},{"nctId":"NCT00441142","phase":"PHASE1, PHASE2","title":"Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors","status":"COMPLETED","sponsor":"Patrick Y. Wen, MD","startDate":"2007-05-25","conditions":"Glioblastoma Multiforme, Gliosarcoma","enrollment":119},{"nctId":"NCT03780569","phase":"NA","title":"TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM","status":"UNKNOWN","sponsor":"NovoCure Ltd.","startDate":"2017-04-27","conditions":"Glioblastoma Multiforme","enrollment":10},{"nctId":"NCT00895960","phase":"PHASE1","title":"Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-05-07","conditions":"Glioblastoma, CNS Disease, Brain Diseases","enrollment":16},{"nctId":"NCT03388372","phase":"PHASE2","title":"Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma","status":"COMPLETED","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2010-08-18","conditions":"Glioblastoma","enrollment":39},{"nctId":"NCT03338075","phase":"","title":"FSRT Combined With TMZ for Large BMs: a PSM Study","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-01-01","conditions":"Brain Metastases, Radiotherapy, Chemotherapy","enrollment":72},{"nctId":"NCT03310372","phase":"PHASE2","title":"Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2008-02-13","conditions":"Glioblastoma Multiforme","enrollment":46},{"nctId":"NCT02329795","phase":"","title":"Image-derived Prediction of Response to Chemo-radiation in Glioblastoma","status":"TERMINATED","sponsor":"Rigshospitalet, Denmark","startDate":"2014-10","conditions":"Glioblastoma","enrollment":16},{"nctId":"NCT01310868","phase":"PHASE2","title":"Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2011-05","conditions":"Glioblastoma","enrollment":59},{"nctId":"NCT00686725","phase":"PHASE4","title":"Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-06-24","conditions":"Glioblastoma","enrollment":99},{"nctId":"NCT01149109","phase":"PHASE3","title":"Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients","status":"COMPLETED","sponsor":"University Hospital, Bonn","startDate":"2010-10","conditions":"Glioblastoma","enrollment":141},{"nctId":"NCT00266812","phase":"PHASE2","title":"Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":35},{"nctId":"NCT00684567","phase":"PHASE2","title":"Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09-27","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT02654106","phase":"PHASE2","title":"Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-10","conditions":"Brain Metastases","enrollment":65},{"nctId":"NCT03082846","phase":"NA","title":"Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial","status":"COMPLETED","sponsor":"Xue Xiaoying","startDate":"2014-01-01","conditions":"Glioma, Radiotherapy, Intensity-Modulated, Maximum Tolerated Dose","enrollment":16},{"nctId":"NCT00813943","phase":"PHASE2","title":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2009-03","conditions":"Glioblastoma","enrollment":265},{"nctId":"NCT02394665","phase":"PHASE2","title":"Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-03","conditions":"Glioblastoma","enrollment":1},{"nctId":"NCT00705198","phase":"","title":"Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Glioma, Astrocytoma","enrollment":1804},{"nctId":"NCT00574964","phase":"PHASE2","title":"Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2005-10","conditions":"Primary Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT00267592","phase":"PHASE2","title":"Safety and Efficacy of Talampanel in Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-12","conditions":"Glioblastoma Multiforme","enrollment":72},{"nctId":"NCT02772094","phase":"PHASE2","title":"Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2005-05","conditions":"Glioblastoma Multiforme, Glioblastoma","enrollment":50},{"nctId":"NCT00085254","phase":"PHASE1, PHASE2","title":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-04","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":112},{"nctId":"NCT01345370","phase":"","title":"Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients","status":"COMPLETED","sponsor":"Center Eugene Marquis","startDate":"2009-03","conditions":"Glioblastoma","enrollment":300},{"nctId":"NCT00704808","phase":"","title":"Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Glioblastoma","enrollment":180},{"nctId":"NCT00725010","phase":"","title":"Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Glioblastoma","enrollment":64},{"nctId":"NCT02385136","phase":"PHASE1, PHASE2","title":"Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2015-04","conditions":"NSCLC","enrollment":135},{"nctId":"NCT00723827","phase":"","title":"Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Glioblastoma, Glioma, Astrocytoma","enrollment":682},{"nctId":"NCT00689221","phase":"PHASE3","title":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2008-09","conditions":"Glioblastoma","enrollment":545},{"nctId":"NCT01952886","phase":"PHASE2","title":"Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients","status":"WITHDRAWN","sponsor":"Duke University","startDate":"","conditions":"Malignant Glioma","enrollment":""},{"nctId":"NCT00650923","phase":"PHASE1","title":"Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":61},{"nctId":"NCT02133677","phase":"PHASE2","title":"A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2014-05","conditions":"Lung Cancer and Breast Cancer Patients With Brain Metastases","enrollment":24},{"nctId":"NCT01015534","phase":"PHASE2","title":"Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2006-01","conditions":"Brain Neoplasms","enrollment":55},{"nctId":"NCT00274833","phase":"PHASE2","title":"Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"David Peereboom","startDate":"2005-10","conditions":"CNS Tumor, Adult","enrollment":27},{"nctId":"NCT00753246","phase":"PHASE3","title":"Nimotuzumab in Adults With Glioblastoma Multiforma","status":"COMPLETED","sponsor":"Oncoscience AG","startDate":"2007-08","conditions":"Adults With Glioblastoma Multiforma","enrollment":150},{"nctId":"NCT00376103","phase":"PHASE1, PHASE2","title":"Radiation Boost for Newly Diagnosed Glioblastoma Multiforme","status":"TERMINATED","sponsor":"Methodist Healthcare","startDate":"2006-08","conditions":"Glioblastoma Multiforme","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":356,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"concomitant temozolomide (TMZ)","genericName":"concomitant temozolomide (TMZ)","companyName":"Alliance for Clinical Trials in Oncology","companyId":"alliance-for-clinical-trials-in-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells. Used for Glioblastoma multiforme, Anaplastic astrocytoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}